Basic Information (Switzerland) Elecon Asia SA (hereinafter referred to as “Elecon”) is a powerful intelligent three-d...
Digital Copyright Ten Major Typical Cases 1.Short Video Copyright Case: Whether a Short Video is Original Has Nothing to...
December 7, 2023 - News of a patent infringement ruling against Apple Watches a few weeks ago caused a flurry of investo...
A long-running dispute between Fresenius Medical Care and Nipro over dialysis technology has concluded in Germany. The Federal Court of Justice declared the patent-in-suit invalid, thereby removing
at the Mannheim local division concerns EP 2 028 981, the patent-in-suit at the Paris local division is EP 3 155 936. Both relate to a juice extractor. In March, the Mannheim division found that NUC
EPO, and an infringement suit was dismissed by Munich Regional Court. Today, the Mannheim local division also dismissed the infringement suit relating to the second patent. Dish accuses Aylo of
The global patent dispute between Nokia and Amazon has ended. Today, the Finnish tech company announced it had signed an agreement with the US company covering the use of Nokia's video technologies
we sent a Japanese lawyer to the Tokyo District Court in order to get access to the case file of what is the highest-profile patent litigation in the history of the video games industry (April 18
argued there was a risk of imminent infringement of its patent EP 1 830 843 B1, which protects the use of nintedanib or nintedanib esylate, from 12 December 2024. The pharma company also owns the related
The settlement had been hinted at in recent days after signs emerged in the US and at the UPC that hearings were no longer taking place. JUVE Patent learned from lawyers involved in the case that the
infringes a patent held by Fresenius Kabi, thus overturning a first-instance decision. Fresenius Kabi alleges that Biogen’s Imraldi has infringed its EP 3 145 488 B1 for a ‘liquid pharmaceutical
Chinese cloud-computing giant Inspur has withdrawn its patent invalidity challenges against Hewlett Packard Enterprise (HPE), signaling a potential shift in the ongoing cross-border intellectual
include in the application,” writes Arnold. But, while “there is no evidence before this Court as to whether the same was true of dapagliflozin and the application for the patent”, Arnold emphasises
CHINA intellectual PROPERTY LAWYERS NETWORK
+86-13910160652
ciplawyers@163.com
